Saturday, May 09, 2020 5:11:36 PM
Recent SNPX News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2024 02:21:09 PM
- Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength • PR Newswire (US) • 12/20/2024 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2024 10:06:45 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2024 10:00:32 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/07/2024 01:54:38 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 11/05/2024 11:01:09 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/28/2024 08:00:16 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 10/10/2024 09:11:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2024 08:30:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2024 08:54:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 01:00:53 PM
- Synaptogenix Announces $5.0 Million Financing • PR Newswire (US) • 09/11/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 09:00:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:30:55 PM
- Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury • PR Newswire (US) • 07/18/2024 01:00:00 PM
- Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis • PR Newswire (US) • 06/26/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 09:03:21 PM
- Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery • PR Newswire (US) • 05/07/2024 01:00:00 PM
- Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing • PR Newswire (US) • 04/24/2024 01:15:00 PM
- Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics • PR Newswire (US) • 04/09/2024 01:15:00 PM
- Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing • PR Newswire (US) • 04/03/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:16:19 PM
GreetEat Corporation Announces Ticker Symbol Change to GEAT on OTC Markets • GEAT • Jan 14, 2025 9:40 AM
Unitronix Corp. Expands Stock Buyback Program, Reducing Outstanding Shares by Total of 165M • UTRX • Jan 14, 2025 8:14 AM
UAV Corp Skyborne Technology Secures $105M in Sales Contract LOIs for Revolutionary DART Series Airships • UMAV • Jan 13, 2025 11:00 AM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) • SNWV • Jan 13, 2025 8:10 AM
SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales • SNWV • Jan 13, 2025 8:08 AM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM